ABUS
HealthcareArbutus Biopharma Corporation · Biotechnology · $860M
What is Arbutus Biopharma Corporation?
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for chronic Hepatitis B virus infection. Headquartered in Warminster, Pennsylvania, the company is building a pipeline of complementary antiviral candidates designed to work toward a functional cure.
Arbutus generates revenue primarily through licensing agreements and research collaborations rather than commercial product sales, as its pipeline remains in clinical development. The company is advancing multiple HBV drug candidates that target different stages of the viral lifecycle — from RNA interference to capsid inhibition and immune reactivation. It also holds intellectual property related to lipid nanoparticle delivery technology, which has generated licensing income through partnerships with other biotechnology companies.
Arbutus was founded in 2007 and is headquartered in Warminster, Pennsylvania.
- AB-729: subcutaneous RNAi candidate targeting HBV replication via GalNAc delivery
- AB-836: oral capsid inhibitor suppressing HBV DNA replication
- AB-161: oral HBV RNA destabilizer reducing viral surface antigen
- AB-101: oral PD-L1 inhibitor designed to reawaken HBV-specific immune response
- Small molecule antivirals targeting coronaviruses including COVID-19
Is ABUS a Good Stock to Buy?
UQS Score rates ABUS as Poor overall, reflecting meaningful challenges across several fundamental dimensions.
The most constructive element in the UQS profile is the Risk pillar, which is rated Good — suggesting the company carries a relatively manageable risk profile compared to many clinical-stage peers. The Growth pillar lands at Neutral, indicating neither a clear growth catalyst nor a deteriorating trajectory at this stage.
Both the Quality and Moat pillars are rated Weak, pointing to limited earnings power and a narrow competitive position. The Valuation pillar is rated Elevated, which may give investors pause given the early-stage nature of the pipeline.
Pro members can view the complete pillar breakdown and underlying financial metrics to form a more complete picture of ABUS. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ABUS pay dividends?
No — Arbutus Biopharma Corporation does not currently pay a dividend.
Arbutus Biopharma does not pay a dividend, which is typical for clinical-stage biopharmaceutical companies. Capital is directed toward research, clinical trials, and pipeline development rather than shareholder distributions. Investors in ABUS are generally seeking potential value from pipeline progress rather than income.
When does ABUS report earnings?
Arbutus Biopharma reports earnings on a quarterly cadence, consistent with US-listed public companies.
As a pre-commercial biotech, Arbutus results are driven largely by licensing revenues, collaboration milestones, and research and development expenditures rather than product sales. Quarterly reports typically focus on pipeline progress, cash runway, and partnership updates.
For the most recent quarter's results and guidance, visit Arbutus Biopharma's investor relations page directly.
ABUS Price History
+56.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
ABUS Long-term Outlook
The fundamental outlook for Arbutus hinges on clinical execution across its HBV pipeline. With a Neutral Growth pillar, the company is not yet demonstrating a clear upward trajectory, though pipeline readouts could shift that picture. The Elevated Valuation pillar suggests the market may already be pricing in optimistic scenarios, which raises the bar for positive surprises. The Good Risk rating provides some reassurance around near-term financial stability.
Growth drivers
- Clinical advancement of AB-729 and AB-836 toward later-stage HBV trials
- Licensing and milestone payments from existing collaboration agreements
- Potential expansion of antiviral IP into new therapeutic partnerships
Key risks
- Clinical trial failure or delays across the HBV pipeline
- Elevated valuation relative to pre-commercial revenue base
- Competitive pressure from larger biotechs pursuing HBV functional cure strategies
ABUS vs Peers
Arbutus operates in a competitive clinical-stage biotech landscape alongside companies pursuing different therapeutic and platform strategies.
Maravai focuses on life science tools and nucleic acid products rather than direct antiviral therapeutics, serving biopharma manufacturers as a supplier.
Sana pursues cell and gene therapy platforms targeting a broad range of diseases, representing a distinct modality from Arbutus's small molecule and RNAi approach.
Theravance concentrates on organ-selective medicines primarily in respiratory and other specialty areas, differentiating it from Arbutus's infectious disease focus.
Frequently Asked Questions
What does Arbutus Biopharma do?
Arbutus Biopharma is a clinical-stage biopharmaceutical company developing treatments for chronic Hepatitis B virus infection. Its pipeline includes RNA interference, capsid inhibition, and immune reactivation candidates. The company also holds lipid nanoparticle delivery technology that has generated licensing income through partnerships with other biotechs.
Does ABUS pay dividends?
No, Arbutus Biopharma does not pay a dividend. As a pre-commercial biotech, the company reinvests available capital into clinical development and research programs. Investors in ABUS are typically focused on pipeline value rather than income generation.
When does ABUS report earnings?
Arbutus Biopharma reports on a quarterly cadence, as is standard for US-listed public companies. For the exact timing of upcoming earnings releases, check the company's investor relations page for the most current schedule.
Is ABUS a good stock to buy?
The UQS Score rates ABUS as Poor overall, with Weak readings on both Quality and Moat pillars and an Elevated Valuation. The Risk pillar is a relative bright spot at Good. Whether ABUS fits a portfolio depends on an investor's risk tolerance and view on the HBV pipeline. Pro members can access the full pillar breakdown for deeper context.
Is ABUS overvalued?
The UQS Valuation pillar for ABUS is rated Elevated, suggesting the current market price may reflect optimistic assumptions relative to the company's pre-commercial fundamentals. For a clinical-stage biotech with no product revenue, valuation is inherently tied to pipeline probability estimates.
How does ABUS compare to its competitors?
Arbutus occupies a focused niche in HBV antiviral development, while peers like Sana Biotechnology pursue cell and gene therapy platforms and Theravance targets respiratory diseases. Maravai operates as a life science tools supplier. Each company represents a distinct strategy within the broader healthcare sector.
What is ABUS's market cap bracket?
Arbutus Biopharma is classified as a small-cap company. This places it in a segment of the market where liquidity can be lower and share price volatility tends to be higher than large- or mega-cap peers, which is worth considering alongside the clinical-stage risk profile.
Who founded Arbutus Biopharma?
Arbutus Biopharma was originally founded as Tekmira Pharmaceuticals Corporation in 2007 before changing its name to Arbutus Biopharma. Detailed founding history, including key individuals involved, is publicly available through the company's official disclosures and corporate history.
Is ABUS a long-term quality investment?
From a long-term quality perspective, the UQS Score currently rates ABUS as Poor, with Weak Quality and Moat pillars limiting its composite standing. Long-term quality indicators favor companies with durable earnings power and competitive advantages — areas where Arbutus has not yet demonstrated strength given its pre-commercial stage.
What is the main competitive advantage of Arbutus Biopharma?
Arbutus's most distinctive asset is its intellectual property in lipid nanoparticle and RNAi delivery technology, which has attracted licensing partnerships with multiple biotechnology companies. Its HBV pipeline also targets a large underserved patient population with limited curative options, which underpins the strategic rationale for its programs.
What sector does ABUS belong to?
Arbutus Biopharma operates in the Healthcare sector, specifically within biopharmaceuticals. It is a clinical-stage company, meaning it does not yet generate revenue from approved commercial products. Investors can explore other [healthcare sector stocks](/sector/healthcare) rated by UQS Score for broader context.
Unlock Full ABUS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare ABUS against sector peers on quality and valuation
- ✓Track pillar changes as new earnings data becomes available
- ✓Screen for stronger-rated small-cap healthcare alternatives
Pro Analysis
ABUS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 59.4 | 72.9 | 11.0 | 43.8 | 100.0 | 98.1 | -0.1 |
| May 22, 2026 | 59.5 | 72.9 | 11.0 | 43.8 | 100.0 | 98.5 | -0.1 |
| May 21, 2026 | 59.6 | 72.9 | 11.0 | 43.8 | 100.0 | 99.1 | -0.1 |
| May 20, 2026 | 59.7 | 72.9 | 11.0 | 43.8 | 100.0 | 99.7 | +0.2 |
| May 17, 2026 | 59.5 | 72.9 | 11.0 | 43.8 | 100.0 | 98.8 | -0.2 |
| May 16, 2026 | 59.7 | 72.9 | 11.0 | 43.8 | 100.0 | 99.5 | 0.0 |
| May 14, 2026 | 59.7 | 72.9 | 11.0 | 43.8 | 100.0 | 100.0 | +35.9 |
| May 11, 2026 | 23.8 | 6.2 | 11.0 | 43.8 | 71.8 | 0.0 | +1.5 |
| May 10, 2026 | 22.3 | 0.0 | 11.0 | 43.8 | 71.8 | 0.0 | -1.5 |
| Apr 2, 2026 | 23.8 | 6.2 | 11.0 | 43.8 | 71.8 | 0.0 | — |
ABUS — Pillar Breakdown
Quality
— 72.9/100 (25%)Arbutus Biopharma Corporation shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 43.8/100 (20%)Arbutus Biopharma Corporation shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 100.0/100 (15%)Arbutus Biopharma Corporation carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 99.3/100 (15%)Arbutus Biopharma Corporation appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
Enterprise value multiple relative to sector median.
Moat
— 11/100 (25%)Arbutus Biopharma Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ABUS.
Score Composition
Financial Data
More Stock Analysis
How is the ABUS UQS Score Calculated?
The UQS (Unified Quality Score) for Arbutus Biopharma Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Arbutus Biopharma Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Arbutus Biopharma Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.